Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinchang Lianyang Granule
- Development stage
- Phase 1
- Lead developer
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Qinchang Lianyang Granule (also known as Qingchang Lianyang Granule) is a traditional Chinese medicine (TCM) herbal formulation developed by the Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine). It is formulated as oral granules and is primarily investigated for the treatment of steroid-dependent ulcerative colitis. The formulation is designed to clear the intestines, resolve dampness, and promote the healing of ulcers (mucosal healing) in patients with active ulcerative colitis, offering a potential alternative or adjunctive therapy to conventional immunosuppressants like azathioprine.
- Other names
- Qingchang Lianyang GranuleQingchang Lianyang formula清肠敛疡方清肠敛疡颗粒
Beyond the preview
Go deeper on Qinchang Lianyang Granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qinchang Lianyang Granule.